Naratriptan NDC 69452-340

NDC codes

FDA NDC Directory

Product NDC (as listed)69452-340Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69452-0340Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69452-340-72	69452034072	1 BLISTER PACK in 1 CARTON (69452-340-72) / 9 TABLET, FILM COATED in 1 BLISTER PACK (69452-340-60)Marketed from Apr 11, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Naratriptan
Generic name (nonproprietary): naratriptan
Active ingredients: Naratriptan hydrochloride — 1 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Bionpharma Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091441
Marketing start: Apr 11, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Serotonin 1b Receptor Agonists (Mechanism)Serotonin 1d Receptor Agonists (Mechanism)
Identifiers: Product ID 69452-340_f91320a2-bfdd-4b9e-a68f-5ec94b77263bSPL ID f91320a2-bfdd-4b9e-a68f-5ec94b77263bSPL set ID 93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6ddaRxCUI 311918, 314135UNII 10X8X4P12Z
Pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N469452034072 followed by a unit qualifier and the quantity

Package 69452-0340-72. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2026.

Indications (excerpt from the label)

Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets, reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. Naratriptan tablets are a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for the acute treatment of migraine with or with…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 091441

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 091441
Product	Strength	Form · route	Labeler	Product NDC
Naratriptan	Naratriptan hydrochloride 2.5 mg/1	Tablet, Film coatedOral	Bionpharma Inc.	69452-341